Bausch + Lomb has a long-standing commitment to advancing ocular health through innovative research and development. The company actively supports Investigator-Initiated Studies (IIS), which are designed to enhance patient care and treatment options in the field of eye health. These studies, typically smaller in scale than Phase IV trials, focus on exploratory research that can lead to significant improvements in disease treatment and patient outcomes. Bausch + Lomb provides funding for these studies based on scientific merit and alignment with its strategic interests, ensuring that the research adheres to the highest ethical standards and regulatory compliance.

In addition to supporting IIS, Bausch + Lomb emphasizes the importance of continuous medical education for healthcare professionals. The company offers grants to facilitate bona-fide scientific research, which is reviewed by the Bausch + Lomb Grants Committee. This initiative not only fosters innovation in ocular health but also aims to improve consumer standards of care, efficacy, and patient satisfaction. The strategic areas of interest for research proposals include various pharmaceutical products and technologies, such as those related to contact lenses and eye drops, which are designed to enhance the overall vision care experience for patients.

United States

We're a leading global eye health organization that is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from the moment of birth through every phase of life. Our comprehensive portfolio of more than 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments. Founded in 1853, we have a significant global research and development, manufacturing and commercial footprint with more than 12,000 employees and a presence in nearly 100 countries.

Bausch & Lomb

Company Details